Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cipla Ltd. Capital/Financing Update 2026

Mar 2, 2026

59275_rns_2026-03-02_55e3fa3f-13d3-4230-a550-67f85e906a28.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [84 x 30] intentionally omitted <==

2[nd] March, 2026

(1) BSE Limited National Stock Exchange of India Limited Listing Department, (2) Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5[th] floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to the provisions of the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that Cipla Limited has entered into a 60:40 joint venture agreement with Kemwell Biopharma Private Limited (‘Kemwell’) on 2[nd] March 2026 for incorporation of a joint venture company in India. The joint venture will undertake the business of developing, applying for and obtaining licenses for and manufacturing, commercialising, importing and exporting biologic products and licensing or outsourcing of any or all such activities.

Kemwell is a premier Asia-based biologics CDMO offering end to end services for global biopharma clients. Its Bangalore cGMP site, certified by the US FDA, includes 5,000 L bioreactor capacity, sterile fill–finish, and advanced development labs for protein therapeutics. Kemwell supports commercial manufacturing as well as R&D and clinical programs for novel biologics and biosimilars.

The details required to be disclosed under the Listing Regulations read with SEBI Circular no. HO/49/14/14(7)2025CFD-POD2/I/3762/2026 dated 30[th] January 2026 on the captioned subject are enclosed to this intimation as Annexure I.

Please take the above information on record.

Yours faithfully,

For Cipla Limited

Digitally signed by RAJENDRA RAJENDRA CHOPRA CHOPRA Date: 2026.03.02 19:51:54 +05'30'

Rajendra Chopra

Company Secretary

Prepared by: Sharina Dsilva

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 41916000 F +91 22 41916120 W www.cipla.com E-mail [email protected] Corporate Identity Numbe r L24239MH1935PLC002380

==> picture [84 x 30] intentionally omitted <==

Annexure – I

Details as per the SEBI Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30[th] January 2026

Sr.
No.
Particulars Details
a) Name of the target entity, details in
brief such as size, turnover etc.
Name of the target entity: Not applicable as the Joint
Venture Company (JV Company) is yet to be
incorporated.
Brief Details such as size, turnover etc:Not applicable
b) Whether the acquisition would fall
within related party transaction(s)
and
whether
the
promoter/
promoter group/ group companies
have any interest in the entity being
acquired? If yes, nature of interest
and details thereof and whether the
same is done at “arm’s length”
Not
applicable.
This
intimation
is
towards
incorporation of a JV Company.
c) Industry to which the entity being
acquired belongs
Pharmaceutical Industry
d) Objects and effects of acquisition
(including but not limited to,
disclosure of reasons for acquisition
of target entity, if its business is
outside the main line of business of
the listed entity)
The JV Company is being incorporated with an
objective to develop, manufacture and commercialise
biologicsfor global markets.
e) Brief details of any governmental or
regulatory approvals required for
the acquisition
Not applicable
f) Indicative
time-period
for
completion of the acquisition
Not applicable
g) Nature of consideration - whether
cash consideration or share swap
and details of the same
Cash consideration
h) Cost of acquisition or the price at
which the shares are acquired
Cost of acquisition: Not applicable
JV partners will initially invest upto INR 10 crores in the
JV Company in their respective JV ratio.

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 41916000 F +91 22 41916120 W www.cipla.com E-mail [email protected] Corporate Identity Numbe r L24239MH1935PLC002380

==> picture [84 x 30] intentionally omitted <==

At the time of incorporation the Company will
subscribe 6,000 shares of INR 10 each at par amounting
to INR 60,000.
i) Percentage
of
shareholding
/
control acquired and / or number of
shares acquired
It is a 60:40 joint venture between Cipla and Kemwell.
j) Brief background about the entity
acquired in terms of products/line
of business acquired, date of
incorporation, history of last 3
years’ turnover, country in which
the acquired entity has presence
and
any
other
significant
information (in brief)
Brief Background:Refer point (c) and (d)
Country:India
Date of Incorporation and Turnover:Not applicable.

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 41916000 F +91 22 41916120 W www.cipla.com E-mail [email protected] Corporate Identity Numbe r L24239MH1935PLC002380